Strattera - Atomoxetine

Strattera is the brand name for atomoxetine, used in the treatment of ADHD. Atomoxetine belongs to the class called selective norepinephrine reuptake inhibitors, which means it selectively inhibits noradrenaline reuptake in the brain. When norepinephrine stays available longer at nerve synapses, many people experience better sustained attention and less impulsive, “act-before-thinking” behaviour ^[1].

Strattera is not a stimulant. It does not aim for a fast “on/off” effect during the day the way stimulant medicines can. The benefit tends to build gradually over several weeks, which fits long-term treatment plans and can feel smoother for many patients.

A quick translation of the jargon helps:

• Norepinephrine (noradrenaline): a brain chemical involved in alertness, attention, and self-control.
• Reuptake: the process where nerve cells “reabsorb” a brain chemical after releasing it.
• Selective norepinephrine reuptake inhibitor: a medicine that blocks norepinephrine reabsorption more than other neurotransmitters, leaving more available to do its job.

Doctor perspectives from ADHD clinics

In clinical practice, prescribers in adult ADHD services often choose Strattera when a patient has a history of stimulant intolerance, prominent anxiety, or a preference for a non-stimulant plan. Many clinicians also like that it can support “all-day” function without a sharp peak, so workdays with meetings late afternoon do not hinge on timing a second dose. A common pattern I hear from doctors is that they judge progress by practical endpoints: fewer unfinished tasks, better follow-through, and reduced impulsive interruptions, not just a rating scale.

Strattera can still cause early side effects, and clinicians plan for them. They often start low and adjust slowly because nausea, sleep changes, and appetite suppression can appear in week one. This approach is consistent with regulator-reviewed product information used across many markets.

Active substance: atomoxetine (as atomoxetine hydrochloride) in hard capsules. Excipients vary by strength and may include capsule fillers, stabilizers, and capsule shell components such as gelatin and coloring agents.

Take Strattera exactly as prescribed for ADHD, and stick to the same time pattern each day.

Practical administration rules that matter:

1. Swallow the capsule whole with water. Do not crush, chew, or open it.
2. It is taken once or twice daily, depending on the prescribed plan. If twice daily, the second dose is usually morning and late afternoon/early evening.
3. It can be taken with or without food. Food may reduce nausea, so taking it with a meal is a reasonable option if your stomach is sensitive.
4. Expect a gradual onset; many people notice clearer benefit after several weeks rather than on the first days.

If you miss a dose, take it when you remember the same day, then continue your normal schedule. Do not take two doses to make up for one. If you stop treatment, do it with your prescriber rather than abruptly, so symptom return can be managed.

• Route: oral (capsules), swallow whole with water; do not open or chew.
• Starting dose: 40 mg once daily (adults and adolescents ≥70 kg).
• Titration: after at least 3 days, increase to 80 mg/day.
• Maintenance: 80 mg/day as 1 dose once daily or divided 40 mg twice daily (morning and late afternoon/early evening).
• Maximum: 100 mg/day.
• With food: may be taken with or without meals.
• Duration: assess response after 2–4 weeks; continue as prescribed for long‑term control if effective.

Strattera, with the active ingredient atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in adults and children. It is prescribed for people who need steadier symptom control or who cannot use stimulant options.

Strattera (atomoxetine) is a non-stimulant ADHD medicine. Stimulant medicines (for example Adderall) increase catecholamine signalling more directly and often have a faster perceived onset. Strattera is usually chosen when the clinical goal is steadier symptom coverage, when stimulants are not tolerated, or when misuse risk is a concern.

What the difference feels like in real life can be practical:

• Stimulants may feel “switched on” within hours on a given day.
• Strattera tends to feel like fewer internal barriers to starting and finishing tasks over time, rather than a strong immediate push.

A real limitation: if you want a medicine that you can take only on exam days or only on workdays, Strattera usually does not fit that pattern. It rewards daily consistency.

• Stopping after 7–10 days because focus did not improve yet. Strattera is not a same-day effect medicine, so week-two decisions are often premature.
• Opening capsules to mix contents for swallowing. This can irritate eyes and mucosa if the powder contacts them, and it can worsen tolerability.
• Chasing insomnia with late caffeine while also taking Strattera later in the day. This combo often keeps sleep fragmented.
• Ignoring pulse and blood pressure trends when feeling wired or getting headaches. Small increases can matter for some patients.
• Skipping doses on weekends and expecting weekday performance to stay steady. Consistency is the point with atomoxetine.

A recurring theme in ADHD clinics is managing expectations about pace. Because atomoxetine builds its effect over weeks rather than hours, prescribers spend the first appointments explaining that the absence of a same-day lift is normal and not a sign the medicine is failing. Setting that frame up front reduces the early drop-outs that happen around week two.

Clinicians also weigh a person's wider picture when choosing it: co-existing anxiety, sleep difficulties, a wish to avoid a controlled stimulant, or a job where an afternoon dip in a stimulant would be disruptive. Practitioners typically open at a low dose and step up gradually, and they track concrete outcomes — tasks completed, deadlines met, fewer impulsive interruptions — alongside routine pulse and blood-pressure checks during titration.